We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.18%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.45B
AUM Growth
+$67.8M
Cap. Flow
-$174M
Cap. Flow %
-5.03%
Top 10 Hldgs %
43.57%
Holding
114
New
15
Increased
22
Reduced
33
Closed
19

Top Buys

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$110M
2
AKRO
Akero Therapeutics
AKRO
+$64.9M
3
VIR icon
Vir Biotechnology
VIR
+$45.6M
4
MDT icon
Medtronic
MDT
+$40.2M
5
VRNA
Verona Pharma
VRNA
+$35.5M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$142M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$137M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$94.1M
4
SNY icon
Sanofi
SNY
+$41.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.57%
2 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VBIV
76
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$4.54M 0.13%
1,381,355
-363,145
-21% -$1.1M
SLRN
77
DELISTED
ACELYRIN
SLRN
$4.18M 0.12%
+200,000
New +$4.09M
SLGC
78
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.46M 0.1%
1,500,000
– –
KRON
79
DELISTED
Kronos Bio
KRON
$3.01M 0.09%
1,752,745
– –
QTRX icon
80
Quanterix
QTRX
$160M
$2.93M 0.08%
130,000
– –
NVNO
81
enVVeno Medical
NVNO
$6.94M
$2.41M 0.07%
22,332
– –
OMIC
82
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.96M 0.06%
78,774
-30,635
-28% -$898K
CYPH
83
Cypherpunk Technologies Inc
CYPH
$64.4M
$1.84M 0.05%
586,733
-85,917
-13% -$431K
ARQT icon
84
PUT
Arcutis Biotherapeutics
ARQT
$3.5B
$1.42M 0.04%
+300,000
New +$3.33M
TVTX icon
85
Travere Therapeutics
TVTX
$5.3B
$1.39M 0.04%
90,748
– –
MRTX
86
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$690K 0.02%
+200,000
New +$8.24M
VRNA
87
CALL
DELISTED
Verona Pharma
VRNA
$675K 0.02%
+500,000
New +$10.7M
PNT
88
PUT
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$675K 0.02%
+500,000
New +$4.41M
XBI icon
89
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$138K ﹤0.01%
150,000
+50,000
+50% +$4.18M
VERU icon
90
Veru
VERU
$35.5M
$107K ﹤0.01%
8,988
-420,833
-98% -$4.93M
MOTS
91
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$60.3K ﹤0.01%
6,002
– –
EQRXW
92
DELISTED
EQRx, Inc. Warrant
EQRXW
$42.5K ﹤0.01%
250,000
– –
CMAXW
93
DELISTED
CareMax, Inc. Warrant
CMAXW
$23.4K ﹤0.01%
60,000
– –
BTAI icon
94
CALL
BioXcel Therapeutics
BTAI
$25.4M
$11K ﹤0.01%
+27,469
New +$9.15M
SRZNW icon
95
Surrozen Inc Warrant
SRZNW
$36.6K
$10K ﹤0.01%
166,666
– –
ADCT icon
96
ADC Therapeutics
ADCT
$140M
– –
-1,495,805
Closed -$2.92M
AVDL
97
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-590,000
Closed -$5.4M
CLOV icon
98
Clover Health Investments
CLOV
$2.22B
– –
-1,500,000
Closed -$1.27M
CTKB icon
99
Cytek Biosciences
CTKB
$563M
– –
-1,289,534
Closed -$11.9M
DRIO icon
100
DarioHealth
DRIO
$51.3M
– –
-15,693
Closed -$1.29M
1 2 3
4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Perceptive Advisors held 114 positions worth $3.45B, up 2% from $3.39B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $174M in Q2 2023, closing 19 positions and reducing 33 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Perceptive Advisors opened a new position in Medtronic worth $41.1M.

  • Perceptive Advisors's largest Q2 2023 buy was Medtronic: 467,000 shares worth $41.1M.
  • Perceptive Advisors added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2023, an estimated $110M increase.
  • Perceptive Advisors's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $142M.
  • Perceptive Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $137M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q2 2023.
  • Perceptive Advisors opened 15 new positions and closed 19 in Q2 2023.
  • Perceptive Advisors's portfolio value rose 2% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.